论文部分内容阅读
目的探讨子宫内膜癌术后应用激素治疗对早期高危型患者预后的影响。方法选取2013年6月至2014年2月早期高危型子宫内膜癌患者70例,将其随机分为观察组和对照组,每组35例,对照组采取常规治疗,观察加用激素治疗,疗程8个月。比较两组雌激素受体(ER)与孕激素受体(PR)阳性率,同时采用酶联免疫吸附试验(ELISA)分析血清CA125抗原、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平,并比较1年内无瘤生存率。结果观察组ER阳性率(94.3%)、PR阳性率(97.1%)、1年内无瘤生存率(91.4%)均高于对照组(P<0.05);治疗后观察组CA125[(5.35±2.76)U/ml]、TNF-α[(15.31±1.52)ng/L]、IL-6[(3.27±0.52)ng/L]低于对照组(P<0.05)。结论子宫内膜癌术后应用激素治疗可有效改善早期高危型患者CA125、ER、PR水平,提高无瘤生存率,改善预后水平,值得临床推广应用。
Objective To investigate the effect of postoperative hormone therapy on the prognosis of early high-risk patients with endometrial cancer. Methods Seventy patients with high-risk endometrial carcinoma from June 2013 to February 2014 were randomly divided into observation group and control group, with 35 cases in each group. The control group was treated with conventional therapy and hormone therapy, Treatment for 8 months. The positive rates of estrogen receptor (ER) and progesterone receptor (PR) in the two groups were compared, and the levels of serum CA125 antigen, tumor necrosis factor-α (TNF-α), interleukin -6 (IL-6) levels, and compare the 1-year disease-free survival rate. Results The ER positive rate (94.3%), PR positive rate (97.1%) and the one-year disease free survival rate (91.4%) in the observation group were significantly higher than those in the control group (P <0.05) ), IL-6 [(3.27 ± 0.52) ng / L] was lower than that of the control group (P <0.05). Conclusion Postoperative hormone therapy can effectively improve the level of CA125, ER and PR in early high-risk patients, improve the tumor-free survival rate and improve the prognosis, which is worthy of clinical application.